Abstracts tagged "Rheumatoid Factor"

Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 2450 • 2015 ACR/ARHP Annual Meeting
Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis
Lance Feller¹, Austin M. Dalrymple², Paul Tuttle IV³, Reema H. Syed³, Peri Pepmueller¹ and Terry Moore⁴, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Pediatric Rheumatology, St. Louis University, St. Louis, MO, ³IM-Rheumatology, Saint Louis University, St. Louis, MO, ⁴Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 495 • 2015 ACR/ARHP Annual Meeting
Prognostic Significance of Residual Inflammation and Autoantibodies for Disease Relapse upon DMARD Suspension in Patients with Rheumatoid Arthritis in Sustained Remission after DAS-Driven Therapy
Antonio Manzo¹, Serena Bugatti¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Barbara Vitolo¹, Carlomaurizio Montecucco¹ and Roberto Caporali², ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of the…
Abstract Number: 2607 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Raymundo Vera-Pineda¹, Alberto Cardenas-de La Garza², Jorge Esquivel-Valerio³, Dionicio A. Galarza-Delgado², Jose Ramon Azpiri-Lopez⁴, Iris J. Colunga-Pedraza², Mario Alberto Garza-Elizondo² and Jesus Zacarias Villarreal-Pérez⁵, ¹Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ³Rheumatology, Hospital Universitario.UANL, Monterrey, Mexico, ⁴Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Tobacco smoke has been associated to anti-cyclic citrullinated peptide (anti-CCP) antibodies positivity. Recently, in wood-smoke-induced chronic obstructive pulmonary disease (COPD) patients without rheumatoid arthritis…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
Abstract Number: 551 • 2015 ACR/ARHP Annual Meeting
Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
R Alten¹, HG Nüßlein², M Galeazzi³, H-M Lorenz⁴, X Mariette⁵, A Cantagrel⁶, M Chartier⁷, G Desachy⁸, C Poncet⁹, C Rauch¹⁰ and M Le Bars¹¹, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Erlangen, Nürnberg, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵Université Paris-Sud, Paris, France, ⁶Purpan Hospital, Toulouse, France, ⁷Chiltern International, Neuilly, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Docs International, Nanterre, France, ¹⁰Bristol-Myers Squibb, Munich, Germany, ¹¹Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In a recent meta-analysis, neither rheumatoid factor (RF) nor anti-cyclic citrullinated peptide (anti-CCP) antibody status were associated with clinical response to treatment with anti-TNF…
Abstract Number: 2676 • 2015 ACR/ARHP Annual Meeting
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Alejandro Garza-Alpirez¹, Mario Alberto Garza-Elizondo², David Vega-Morales², Cassandra Skinner-Taylor², Ricardo Ramírez³, Roberto Negrete-López⁴, Jorge Esquivel-Valerio², Miguel Villarreal-Alarcon² and Andrés Mendiola¹, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 2021 • 2014 ACR/ARHP Annual Meeting
The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults
Chisun Min¹, Mitsumasa Kishimoto¹, Gautam A. Deshpande², Shunya Kaneshita¹, Masei Suda¹, Yuri Ohara¹, Yoichiro Haji¹, Ryo Rokutanda¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi¹, Akira Takeda³, Yukio Matsui¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ³Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan
Background/Purpose Rheumatoid arthritis (RA) has been shown to be a risk factor for cardiovascular disease (CVD). Both elevated rheumatoid factor (RF) and anti-citrullinated protein antibodies…
Abstract Number: 1560 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis
Frank Behrens^1,2, Michaela Koehm^2,3, Eva C. Scharbatke⁴, Bianca Wittig⁵, Marc Schmalzing⁴, Holger Gnann⁶, H M Lorenz⁷, Diamant Thaci⁸ and Harald Burkhardt^1,9, ¹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, ²Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ³Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ⁴Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ⁵Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁶Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lübeck, Germany, ⁹Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany
Background/Purpose Osteoporosis is an important comorbidity in patients with rheumatic diseases, but risk factors for osteoporosis in Psoriatic Arthritis (PsA) patients have not been explored. …
Abstract Number: 1404 • 2014 ACR/ARHP Annual Meeting
Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis
Muhammad Imran¹, Shanley O'brien², Mark Hamblin³ and Mehrdad Maz⁴, ¹Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Internal Medicine, Kansas University Medical Center, Kansas city, MO, ³Pulmonary and Critical Care Medicine, ILD Clinic, Kansas University Medical Center, Kansas city, MO, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Interstitial lung disease (ILD) can be idiopathic or associated with underlying etiologies including rheumatoid arthritis (RA). The purpose of this study is to determine…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 453 • 2014 ACR/ARHP Annual Meeting
In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA
Jerry A. Molitor¹, Bryan S. Michalowicz², Ryan T. Demmer³, Jane H. Buckner⁴, Mark H. Wener⁵ and William H. Robinson⁶, ¹Rheumatology, University of Minnesota, Minneapolis, MN, ²Department of Developmental and Surgical Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ³Epidemiology, Columbia Univ. Mailman School of Public Health, New York, NY, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Rheumatology & Lab Med, University of Washington, Seattle, WA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Periodontal disease (PD) and RA share the risk factors HLA DR B1 shared epitope (SE) and tobacco exposure (TE). PD may represent a risk…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].